Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Agios Pharma. The associated price target remains the same with $56.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the recent positive developments surrounding Agios Pharma’s drug, Pyrukynd. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a favorable opinion for Pyrukynd’s use in treating anemia associated with both transfusion-dependent and non-transfusion-dependent thalassemia. This endorsement is supported by strong Phase 3 trial data, which enhances confidence in its potential FDA approval.
Furthermore, Agios has strategically partnered with Avanzanite Bioscience to commercialize Pyrukynd in Europe, establishing a clear path for international market expansion. Despite a procedural delay in the U.S. approval process, the absence of new safety or efficacy concerns bolsters confidence in eventual approval. Additionally, recent approval in Saudi Arabia and ongoing reviews in the UAE further support the drug’s broad market potential, contributing to the Buy rating.
According to TipRanks, Bodnar is a 3-star analyst with an average return of 3.5% and a 37.50% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Atossa Therapeutics, and Agios Pharma.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $51.00 price target.